News and Trends 22 Jan 2018
New Triple Combination Therapy Boosts Colorectal Cancer Survival
Pierre Fabre and Array BioPharma's combination therapy for colorectal cancer has improved progression-free survival in a Phase III trial. French…
Pierre Fabre
- Latest Posts
News and Trends 22 Mar 2017
France’s 2nd Biggest Pharma Enters New Partnership for Immunotherapies
With its new Fund for Innovation, Pierre Fabre will collaborate with H-Immune to use its 'In Vitro Immunization' (IVI) platform for the…
News and Trends 24 Feb 2017
What are the Current Challenges in the Booming Field of ADCs?
ADCs are overcoming the challenges of first generations and returning with a vengeance. I attended the World ADC Conference to hear…
News and Trends 10 Nov 2016
European Biotech is working hard to Beat back Melanoma
Immunocore and Pierre Fabre have been representing Europe in this years' Society for Melanoma Research Congress. This type of cancer may…
ADVERTISEMENT
News and Trends 29 Jun 2016
How to Survive the Valley of Death as a Biotech Startup?
Over the past decade there has been an unprecedented restructuring of R&D in pharma whereas building a successful biotech company…
News and Trends 15 Apr 2016
Pierre Fabre partners for Open Innovation in Infectious Disease
Pierre Fabre has a new partnership for its Open Innovation programme based on an extensive plant library. It will now…
News and Trends 17 Mar 2016
“We have Reshaped how Innovation occurs inside Pierre Fabre”
This is what Laurent Audoly, Head of R&D of Pierre Fabre, told me at the SACHS conference in Zurich last…
News and Trends 3 Feb 2016
France’s 3rd Largest Pharma Company Finally Opens up to Biotech Innovation
Open Innovation is now everywhere, even Pharma. So, just today in France, the opening of the Pierre Fabre Fund for Innovation…
News and Trends 19 Nov 2015
This 10,000 Employee French Pharma is Finally Entering the Biotech Partnership Race
Biotech is getting more and more about partnering rather than doing everything alone. Some conservative Pharmas, which worked to more…
